Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D
Executive Summary
Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29
You may also be interested in...
Schering Vanceril phase-out
Schering-Plough completely discontinues Vanceril with phase-out of 42 mcg strength, company says. Vanceril (beclomethasone) 84 mcg was previously discontinued as part of Schering's consent decree with FDA (1"The Pink Sheet" May 27, p. 13). The lower strength of the asthma drug had been on back-order for some time, Schering said. Vanceril generated $82 mil. in sales in 2001...
Serono Rebif Approval Is First Orphan Drug Challenge Based On Efficacy
FDA's licensure of Serono's Rebif marks the first time the agency has overridden orphan drug exclusivity based on an efficacy endpoint, a March 7 1Office of Orphan Products Development memo outlining FDA's rationale for the approval states
Ivax acquires two Elan products
Ivax is acquiring Elan's marketed intranasal flunisolide products Nasarel and Nasalide, indicated for treatment of seasonal and perennial allergic rhinitis